Mendus AB (Sweden) Today
| IMMU Stock | SEK 7.03 0.25 3.43% |
PerformanceVery Weak
| Odds Of DistressAbout Average
|
Mendus AB is selling for under 7.03 as of the 17th of March 2025; that is 3.43% down since the beginning of the trading day. The stock's last reported lowest price was 6.95. Mendus AB has 46 percent odds of going through some form of financial distress in the next two years and has generated negative returns to investors over the last 90 days. The performance scores are derived for the period starting the 17th of December 2024 and ending today, the 17th of March 2025. Click here to learn more.
Its lead product is ilixadencel, which is in Phase II clinical trial for the treatment of kidney cancer and Phase IbII clinical trials for the treatment of head and neck cancer, non-small cell lung cancer, and gastric cancer, as well as is in a Phase III clinical trials to treat liver cancer and gastrointestinal stromal tumors. The company has 199.4 M outstanding shares. More on Mendus AB
Moving against Mendus Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Mendus Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Mendus AB's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Mendus AB or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Business Concentration | Biotechnology, Healthcare (View all Sectors) |
Mendus AB (IMMU) is traded on Stockholm Exchange in Sweden and employs 31 people. The company currently falls under 'Small-Cap' category with a current market capitalization of 427.98 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Mendus AB's market, we take the total number of its shares issued and multiply it by Mendus AB's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Mendus AB operates under Healthcare sector and is part of Biotechnology industry. The entity has 199.4 M outstanding shares.
Mendus AB has accumulated about 155.31 M in cash with (138.03 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.94.
Check Mendus AB Probability Of Bankruptcy
Ownership AllocationMendus AB maintains a total of 199.4 Million outstanding shares. Mendus AB holds significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Mendus Ownership Details
Mendus AB Risk Profiles
Although Mendus AB's alpha and beta are two of the key measurements used to evaluate Mendus AB's performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 2.9 | |||
| Standard Deviation | 3.73 | |||
| Variance | 13.9 | |||
| Risk Adjusted Performance | (0.04) |
Mendus Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Mendus AB without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Share Portfolio Now
Share PortfolioTrack or share privately all of your investments from the convenience of any device |
| All Next | Launch Module |
Mendus AB Corporate Management
Elected by the shareholders, the Mendus AB's board of directors comprises two types of representatives: Mendus AB inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Mendus. The board's role is to monitor Mendus AB's management team and ensure that shareholders' interests are well served. Mendus AB's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Mendus AB's outside directors are responsible for providing unbiased perspectives on the board's policies.
| MD MBA | Bus Advisor | Profile | |
| Leopold Bertea | Chief Officer | Profile | |
| Lotta Ferm | Chief Officer | Profile | |
| Erik Manting | Chief Officer | Profile | |
| Jeroen MD | Chief Officer | Profile | |
| PerOlof Gunnesson | Advisor Contracts | Profile | |
| Alex MD | CoFounder Officer | Profile |
Additional Tools for Mendus Stock Analysis
When running Mendus AB's price analysis, check to measure Mendus AB's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mendus AB is operating at the current time. Most of Mendus AB's value examination focuses on studying past and present price action to predict the probability of Mendus AB's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mendus AB's price. Additionally, you may evaluate how the addition of Mendus AB to your portfolios can decrease your overall portfolio volatility.